This excerpt taken from the TPTX 8-K filed Jun 8, 2006.
Neuron. In this study, it was shown in mice that NGX267 lowered brain levels of A(-42 and could prevent the formation of both the amyloid plaque and neurofibillary tangles that are the pathological hallmarks of Alzheimers Disease. The authors concluded that NGX267 could potentially have important effects in delaying or preventing the progression of Alzheimers Disease.
Both companies have some very promising pre-clinical candidates that are highlighted here.
As Gosse previously mentioned, BNC is a highly selective butyrylcholinesterase inhibitor in late stage pre-IND development for the treatment of severe Alzheimers Disease.
NGX292, our follow-up muscarinic agonist and NGX555 are two additional IND candidates that are being targeted for the treatment of Alzheimers Disease.
NGX555, our gamma/secretase modulator, is a particularly significant compound as it comes directly from the discovery function of TorreyPines, and we believe validates the scientific excellence of the group.
These compounds, along with BNC, represent an important part of the future of the company.
Together with NGX267, Phenserine and Posiphen, these six compounds give the combined company, in my opinion, one of the strongest and most diversified pipelines for Alzheimers Disease in the pharmaceutical industry.
Before we close, I want to review the companys anticipated clinical milestones during the next 12-months.
In Migraine and Chronic Pain, Tezampanel is expected to enter into a Phase IIb trial for treatment of migraine and we plan to file an IND for NGX426 and start a Phase I trial with the drug.
In our Alzheimers Disease Franchise, the ongoing Phase I trials with Posiphen for Alzheimers Disease progression should be completed, and data from the Phase I single dose study of NGX267 in healthy elderly should become available. We plan to begin a multiple dose Phase I trial with NGX267, and we plan to start a Phase I trial with BNC.
At this point, let me turn things over again to Gosse who will take you through the remainder of the presentation